Desvenlafaxine, Khedezla (desvenlafaxine) is a small molecule pharmaceutical. Desvenlafaxine was first approved as Desvenlafaxine on 2013-03-04. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter and sodium-dependent serotonin transporter. In addition, it is known to target sodium-dependent dopamine transporter.
|Trade Name||Desvenlafaxine, Khedezla|
|Indication||major depressive disorder|
|Drug Class||Antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake|